Clinical Probiotic Strains · Fermented/Probiotic
Lactobacillus rhamnosus 271
Preliminary EvidenceCompound
Hermetica Superfood Encyclopedia
Lactobacillus rhamnosus 271 is a probiotic strain that produces bacteriocins and organic acids, including lactic acid, to inhibit pathogenic bacterial adhesion and colonization in the gut. Its primary mechanism involves competitive exclusion at intestinal epithelial receptor sites and modulation of mucosal immune signaling via toll-like receptor 2 (TLR2) pathways.
Lactobacillus rhamnosus 271 (DSM 6594) is a specific strain of Gram-positive, rod-shaped bacterium that naturally occurs in the human gut and fermented foods. This clinical probiotic strain is cultured and propagated under controlled fermentation conditions and demonstrates antimicrobial activity against pathogens.
No human clinical trials or RCTs specifically for L. rhamnosus 271 (DSM 6594) are available. Evidence is limited to related strains, including a randomized double-blind placebo-controlled trial (n=36) of L. rhamnosus PRSF-L477 at 1×10¹¹ CFU/day for 28 days showing safety and increased fecal lactobacilli. No PMIDs are provided for strain 271-specific trials.
No clinically studied dosages are available specifically for L. rhamnosus 271. Related L. rhamnosus strains have been studied at 10⁹-10¹¹ CFU/day in powder form, with PRSF-L477 showing safety at 1×10¹¹ CFU/day for 28 days. Consult a healthcare provider before starting any new supplement.
Lactobacillus rhamnosus 271 is a probiotic microorganism, not a conventional food ingredient, so macronutrient contribution per serving is negligible (calories ~0-2 kcal per typical dose of 1-10 billion CFU). Key bioactive components include: (1) Surface-layer proteins (S-layer proteins) and moonlighting proteins that mediate host-microbe interactions and mucus adhesion; (2) Lipoteichoic acids (LTAs) in cell wall, which modulate immune signaling via TLR2 pathways; (3) Exopolysaccharides (EPS) produced during fermentation, contributing to gut mucosa protection and biofilm formation — EPS yield in L. rhamnosus strains typically ranges 50–200 mg/L in culture; (4) Short-chain fatty acids (SCFAs) generated as metabolic byproducts, primarily lactic acid (the primary fermentation end-product, D- and L-isomers), with trace acetic acid; lactic acid output in L. rhamnosus cultures approximately 8–15 g/L under optimal conditions; (5) Bacteriocins and antimicrobial peptides (strain-specific, evidence for L. rhamnosus 271 specifically is limited, but class II bacteriocins are documented in related strains); (6) B-vitamin synthesis potential: L. rhamnosus strains are documented to produce folate (B9) at approximately 30–120 ng/mL in fermented matrices and riboflavin (B2) in trace amounts, though strain-271-specific quantification is not established in published literature; (7) Peptidoglycan fragments (muramyl dipeptides) released during cell turnover, which activate NOD2 innate immune receptors; (8) Conjugated linoleic acid (CLA) biosynthesis reported in some L. rhamnosus strains at low levels (~0.1–0.5 mg/g cell dry weight). Bioavailability note: As a live organism, the 'nutritional' contribution is functional rather than caloric; viability at point of consumption is critical, with L. rhamnosus 271 demonstrating moderate gastric acid tolerance (survival ~10–40% through simulated gastric conditions at pH 2.0 for 2 hours, consistent with L. rhamnosus species data) and good bile salt resistance (0.3% ox bile tolerance documented for species). Protein content of the bacterial biomass itself is approximately 50–60% of dry cell weight, but this is not bioavailable in conventional nutritional terms at probiotic dosing levels.
Lactobacillus rhamnosus 271 produces lactic acid and bacteriocins that lower luminal pH and disrupt pathogen membrane integrity, reducing adhesion of organisms such as Staphylococcus aureus and Escherichia coli O157:H7 to intestinal epithelial cells. The strain engages pattern recognition receptors, particularly TLR2 and TLR4, on intestinal epithelial and dendritic cells, promoting anti-inflammatory cytokine profiles including increased IL-10 and decreased TNF-α. Competitive exclusion at intestinal mucin glycoprotein binding sites further prevents pathogen colonization by physically occupying adhesion receptors.
Evidence for L. rhamnosus 271 specifically is limited, with most data extrapolated from broader L. rhamnosus strain research, including well-characterized strains like GG and PRSF-L477. General L. rhamnosus studies demonstrate a 44% reduction in S. aureus adhesion in in vitro epithelial cell assays and documented protection against E. coli O157:H7 in animal models. The related strain PRSF-L477 showed transient increases in gut lactobacilli populations during active supplementation, though colonization was not persistent post-supplementation. Strain-specific clinical trials for L. rhamnosus 271 with defined sample sizes and endpoints are currently lacking, requiring cautious extrapolation of efficacy claims.
Lactobacillus rhamnosus 271 is generally regarded as safe (GRAS status) for healthy adults, with the most commonly reported side effects being mild and transient gastrointestinal symptoms such as bloating and flatulence during initial supplementation. Immunocompromised individuals, those with central venous catheters, or patients post-cardiac surgery face a rare but documented risk of probiotic bacteremia and should avoid use without physician supervision. Co-administration with broad-spectrum antibiotics such as fluoroquinolones or metronidazole may significantly reduce viable bacterial counts and diminish efficacy; a 2-hour separation window is recommended. Pregnancy and lactation safety data are limited for this specific strain, though general L. rhamnosus use during pregnancy has shown a favorable safety profile in several studies.
